Table 1.

Current clinical trials in liver fibrosis.

Target	Categories	Agent	Phase of Clinical Trial	Ref.
Targeting liver lipid metabolism and oxidative stress	Molecule compounds	ACC inhibitors Firsocostat PF-05221304	Phase II Phase II	[27,70,71]
		SCD1 inhibitors Aramchol	Phase III	[28]
		FGF agonists Aldafermin Pegbelfermin Efruxifermin	Phase II Phase II Phase II	[29,30,31,32]
		THR beta agonists Resmetirom K2809-201	Phase III Phase II	[35,36,37]
		FXR agonists Obeticholic acid Tropifexor Cilofexor	Phase III Phase II Phase II	[38,39,40,42,72]
		PPAR agonists Elafibranor Lanifibranor Saroglitazar Seladelpar	Phase III Phase II Phase II Phase II	[47,73,74,75]
		ASK1 inhibitors Selonsertib	Phase III	[76]
		GLP-1 receptor agonists Liraglutide Semaglutide Trizepatide	Phase II Phase II Phase II	[50,51,52,77]
		SGLT inhibitors Ipragliflozin Dapagliglozin	Phase II Phase II	[78]
	Antibodies	FGFR1c/KLB	Phase II	[53]
Targeting liver inflammation and cell death	Molecule compounds	CCR2/CCR5 inhibitors Cenicriviroc	Phase III	[79]
		Mitochondrial pyruvate carrier MSDC-0602K	Phase II	[80]
	Antibodies	CB1 antibody Nimacimab	Phase I	[54]
		Anti-IL-17 antibody Secukinumab	Phase I	[81]
		Anti-CCL24 antibody CM-101	Phase II	[55]
	Natural compounds	Berberine (BBR)	Phase II	[56]
		Silymarin	Phase II	[57]
		Resveratrol (RES)	Phase II	[82]
Targeting liver fibrosis	Molecule compounds	Galectin 3 inhibitors GR-MD-02	Phase III	[83]
		ARB inhibitors Losartan	Phase III	[84,85]
		Tyrosine kinase inhibitors Sorafenib	Phase II	[86,87]
	Antibodies	LOXL2 inhibitors	Phase II	[88]
		Integrin aV inhibitors 3G9	Phase II	[89]
		CD105 inhibitors TRC105	Phase II	[60]
	Gene therapy	siHSP47	Phase II	[62]